METHAMPHETAMINE BDBM50359499 (S)Methamphetamine
BDBM50359500 CHEMBL1927030 (R)Methamphetamine
BDBM50009057 (R)Methyl-(1-methyl-2-phenyl-ethyl)-amine METHAMPHETAMINE METHAMPHETAMINE (-) METHAMPHETAMINE (+) Methyl-(1-methyl-2-phenyl-ethyl)-amine Methyl-(1-methyl-2-phenyl-ethyl)-amine(methamphetamine)
3,4-methylenedioxymethamphetamine CHEMBL43048 DL-(3,4-Methylenedioxy)methamphetamine US11767305, Compound MDMA (RS)-3,4-(methylenedioxy)methamphetamine BDBM50010588 N-Methyl-3,4-methylenedioxyamphetamine 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine N,alpha-dimethyl-1,3-benzodioxole-5-ethanamine 1-(1,3-Benzodioxol-5-yl)-N-methyl-2-propanamine MDMA
- Dose Response confirmation of Image-Based HTS for Selective Agonists for NTR1 Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG) Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA) Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN) Grant Proposal Number: 1 R03 MH089653-01 Assay Provider: Dr. Lawrence Barak, Duke University Medical Center Addiction leading to abuse should be treatable by pharmacological approaches, and programs that identify new drugs to treat methamphetamine abuse address an immediate goal of the National Institute on Drug Abuse (NIDA) that new approaches are needed for treating METH addiction. Currently, small molecule drug-like compounds are not available for treating METH abuse. Neurotensin receptor 1 (NTR1) peptide agonists produce behaviors that are exactly opposite to the psychostimulant effects observed with methamphetamine abuse, such as hyperactivity, neurotoxicity, psychotic episodes, and cognitive deficits, and repeated administrations of NTR1 agonists do not l